Schwartz Investment Counsel’s Quest Diagnostics DGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$18.8M Hold
95,900
0.67% 51
2025
Q4
$16.6M Hold
95,900
0.58% 57
2025
Q3
$18.3M Hold
95,900
0.61% 56
2025
Q2
$17.2M Hold
95,900
0.57% 56
2025
Q1
$16.2M Hold
95,900
0.56% 51
2024
Q4
$14.5M Sell
95,900
-166
-0.2% -$25.8K 0.52% 51
2024
Q3
$14.9M Hold
96,066
0.53% 55
2024
Q2
$13.1M Hold
96,066
0.49% 58
2024
Q1
$12.8M Hold
96,066
0.47% 58
2023
Q4
$13.2M Hold
96,066
0.52% 56
2023
Q3
$11.7M Hold
96,066
0.5% 59
2023
Q2
$13.5M Hold
96,066
0.57% 51
2023
Q1
$13.6M Hold
96,066
0.59% 48
2022
Q4
$15M Hold
96,066
0.68% 46
2022
Q3
$11.8M Sell
96,066
-166
-0.2% -$21.9K 0.61% 47
2022
Q2
$12.8M Hold
96,232
0.62% 45
2022
Q1
$13.2M Sell
96,232
-16,300
-14% -$2.27M 0.55% 46
2021
Q4
$19.5M Sell
112,532
-70,000
-38% -$10.7M 0.76% 44
2021
Q3
$26.5M Sell
182,532
-40,000
-18% -$5.85M 1.09% 34
2021
Q2
$29.4M Hold
222,532
1.18% 31
2021
Q1
$28.6M Hold
222,532
1.24% 33
2020
Q4
$26.5M Hold
222,532
1.2% 34
2020
Q3
$25.5M Hold
222,532
1.29% 33
2020
Q2
$25.4M Buy
222,532
+33,132
+17% +$3.51M 1.38% 32
2020
Q1
$15.2M Buy
+189,400
New +$19.6M 1.01% 41

Other funds holding DGX

Schwartz Investment Counsel's DGX Position: Q1 2026 in Review

Schwartz Investment Counsel held its Quest Diagnostics (DGX) position steady in Q1 2026 at 95,900 shares worth $18.8M. The position accounts for 0.67% of the portfolio, ranked #51.

Schwartz Investment Counsel first reported a position in DGX in Q1 2020 and has held it in 25 quarters since. The position peaked at $29.4M in Q2 2021. 1,064 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

  • Schwartz Investment Counsel held 95,900 shares of Quest Diagnostics worth $18.8M as of Q1 2026.
  • Schwartz Investment Counsel left its Quest Diagnostics share count unchanged in Q1 2026.
  • Quest Diagnostics made up 0.67% of Schwartz Investment Counsel's portfolio in Q1 2026, its #51 holding.
  • Schwartz Investment Counsel first reported a position in Quest Diagnostics in Q1 2020 and has held it in 25 quarters since.
  • Schwartz Investment Counsel's Quest Diagnostics position peaked at $29.4M in Q2 2021.
  • 1,064 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on Schwartz Investment Counsel's 13F filing for Q1 2026, filed 4 May 2026.